

COVID-19: Third dose booster vaccine effectiveness against infection, hospitalisations and death in patients with cancer

European Journal of Cancer

175, 1-10

DOI: [10.1016/j.ejca.2022.06.038](https://doi.org/10.1016/j.ejca.2022.06.038)

Citation Report

#	ARTICLE	IF	CITATIONS
3	SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies. <i>Seminars in Hematology</i> , 2022, 59, 192-197.	1.8	5
4	Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer. <i>JAMA Oncology</i> , 2023, 9, 188.	3.4	18
5	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	1.3	2
6	Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. <i>Annals of the Academy of Medicine, Singapore</i> , 2023, 52, 8-16.	0.2	1
7	Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study. <i>Vaccines</i> , 2023, 11, 493.	2.1	0
8	COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review. <i>Clinical Oncology</i> , 2023, , .	0.6	2
9	Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews. <i>Expert Review of Vaccines</i> , 2023, 22, 341-365.	2.0	4
10	Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	12
11	Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. <i>British Journal of Haematology</i> , 2023, 201, 813-823.	1.2	7
12	COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore. <i>Hereditary Cancer in Clinical Practice</i> , 2023, 21, .	0.6	0